Enhancing diabetes care with real-time continuous glucose monitoring (CGM) is the focus of Real-Time Real Talk, the go-to podcast for healthcare professionals in the U.S. Whether you're an endocrinologist, primary care physician, diabetes educator, or pharmacist, this show provides expert insights and real-world applications to help you optimize patient outcomes with CGM technology. Each month, Real-Time Real Talk brings you in-depth conversations with leading clinicians, researchers, and industry experts, diving into: How to integrate real-time CGM into your practice – Learn best practices for onboarding patients and interpreting CGM data The latest clinical evidence – Explore groundbreaking studies on real-time CGM and its impact on glucose tracking Real-world success stories – Hear firsthand experiences from healthcare providers and patients using Dexcom G7 and Stelo to manage type 1 diabetes, type 2 diabetes and prediabetes. Episode topics have included: Type 2 Diabetes Management Through Glucose Tracking: How CGM Improves Patient Outcomes with Dr. Thomas Grace and Dr. William Polonsky Charting a New Path: How Glucose Sensors are Driving Behavior Change in Prediabetes and Type 2 Diabetes with Emily Cornelius, Registered Dietitian Empowering Diabetes Care: Revolutionizing Hospital Discharge Planning with CGM Technology with David Tulle Real-Time Real Talk is your trusted source for staying up to date on CGM advancements. Hosted by Cher Pastore (MS, RD, CDCES, BC-ADM), she is a registered dietitian and certified diabetes care and education specialist, holding a Master of Science in Nutrition from New York University and a Bachelor of Arts in Psychology from University of Massachusetts Boston. She is also a Director of clinical education at Dexcom. Prior to joining Dexcom, Cher was in clinical practice for more than 10 years, specializing in diabetes technology. While in practice, she developed a love of using CGM as a tool in diabetes care. Cher has been featured in such publications as People, D-Life, Everyday Health, and Diabetes Daily, and has appeared in broadcasts on SiriusXM, Extra TV, Channel 5, Channel 7 News. Now, she's excited to share her expertise on a medical podcast. Dexcom is a leader in real-time CGM technology, empowering patients and healthcare providers with accurate, real-time glucose insights. Dexcom has won more than 20 awards over the last 2 years including: 2025 CES Innovation Award Honoree 2023 Healthcare Marketing Impact Award - Film/TV/Video Campaign of the Year ◦ Dexcom Super Bowl Commercial with Nick Jonas and everyday ‘warriors’ 2024 German Design Award – Dexcom G7 CGM System Learn more at dexcom.com. Want to get involved with the show? You can reach us at Cher.pastore@dexcom.com to: Bring Dexcom to your event Be a guest on the show Ask Cher a question If you like Diabetes Core Update, Juicebox Podcast: Type 1 Diabetes, The Huddle: Conversations with the Diabetes Care Team, you’ll enjoy Real-Time Real Talk.
Site
RSS
Apple
Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
Empowering Diabetes Care: How Dexcom Real-Time CGM Supports Pregnant Patients and Enhances Diabetes Management with Expert Insights from Rachel Stahl Salzman
Épisode 26
lundi 9 juin 2025 • Durée 27:44
Pregnant Patients are Empowered by Real-Time Continuous Glucose Monitoring (CGM): How Biosensor Technology Supports Type 1 Diabetes, Type 2 Diabetes, Prediabetes, and Gestational Diabetes
How does real-time data from Continuous Glucose Monitoring (CGM) reshape how we talk about food, exercise, and metabolic health Exploring how CGM - and tools like Dexcom and Stelo are empowering people with type 1 diabetes, type 2 diabetes, and even prediabetes to better understand their glucose patterns and take charge of their diabetes management is host Cher Pastore, MS, RD, CDCES, BC-ADM, joined by Rachel Stahl Salzman, a registered dietitian and certified diabetes education specialist at Weill Cornell.
Rachel shares practical insights from her work in diabetes treatment, including with pregnant patients managing gestational diabetes. She also discusses her recent study presented at Advanced Technologies & Treatments for Diabetes (ATTD), where CGM use helped women with gestational diabetes feel more confident and in control of their care.
From glucose tracking to blood sugar monitoring, this episode explores how biosensor technology supports more personalized, effective diabetes management - not just for patients, but for endocrinologists and primary care providers too.
Whether you’re focused on diabetes treatment, nutrition, or simply curious about the future of diabetes technology, this episode of Real-Time Real Talk reveals how CGM is making care more precise, proactive, and powerful.
Brought to you by Dexcom https://provider.dexcom.com/education-research/podcast
Type 2 Diabetes Management with CGM: Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Épisode 25
mardi 6 mai 2025 • Durée 41:21
How can Continuous Glucose Monitoring (CGM) help people with type 2 diabetes feel more empowered and in control of their health? Exploring compelling new research presented at the Advanced Technologies & Treatments for Diabetes (ATTD) conference is host Cher Pastore, MS, RD, CDCES, BC-ADM, and guest Sim Singh, Senior Director of Behavioral and Translational Science at Dexcom.
Together, they unpack findings from a 30-day study of Dexcom G7 use in people with type 2 diabetes, including those not on insulin. The results show significant improvements in glucose tracking, behavioral shifts like better nutrition and increased physical activity, and enhanced metabolic health and confidence - especially among CGM-naive users. Sim also shares insights from a Canadian trial and discusses how CGM is transforming diabetes education, not only for patients but for endocrinologists and primary care providers as well.
Whether it’s supporting blood sugar monitoring, enabling personalized diabetes treatment, or simply helping people better understand their glucose patterns, this conversation highlights how CGM and biosensor technology are reshaping diabetes management - for people with type 1 diabetes, type 2 diabetes, and even prediabetes.
Unleashing the Power of Partnerships: Tandem Control IQ & Dexcom G7
Épisode 16
mercredi 20 décembre 2023 • Durée 23:57
In this episode of Dexcom’s Real Time Real Talk, we’re speaking to Tandem’s Medical Director, Jordan Pinkster. Jordan is a pediatric endocrinologist by training, but has been involved in clinical trials and the development of automated insulin delivery products for many years. Our second guest is Kristy Castillo, the clinical solutions manager at Tandem who is also a nurse, diabetes educator and lives with type one diabetes herself. We’ll discuss Tandem products including the sleek new number 1 one rated AID system, the t:slim X2 insulin pump, we’ll talk about how it integrates with the Dexcom G6 and G7 and Kristy also shares her first-hand experience of using it. Finally we’ll discuss the advantages of connecting your AID system to your smartphone where possible, not just for those with diabetes but also for health care professionals.Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older.Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.Dr Jordan Pinsker and Kristy Castillo are employees of Tandem Diabetes Care. About Tandem Diabetes Care: https://www.tandemdiabetes.com/en-gb/homeWarning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.Dexcom Provider website: https://provider.dexcom.com/Tandem Control IQ Clinical Evidence: https://www.tandemdiabetes.com/en-gb/homeReferences:1. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Sep;23(9):601-608. doi: 10.1089/dia.2021.0097. Epub 2021 Apr 21. PMID: 33784196; PMCID: PMC8501470.2. Roy W. Beck, Lauren G. Kanapka, Marc D. Breton, Sue A. Brown, R. Paul Wadwa, Bruce A. Buckingham, Craig Kollman, and Boris Kovatchev.A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.Diabetes Technology & Therapeutics.May 2023.329-342.http://doi.org/10.1089/dia.2022.05583. S.A. Brown, B.P. Kovatchev, D. Raghinaru, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes N Engl J Med 2019;381:1707-17. DOI: 10.1056/NEJMoa19078634. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP; iDCL Trial Research Group. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med. 2020 Aug 27;383(9):836-845. doi: 10.1056/NEJMoa2004736. PMID: 32846062; PMCID: PMC7920146.5. Marc D. Breton and Boris P. Kovatchev One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology, Diabetes Technology & Therapeutics 2021 23:9, 601-608 6. Boris P. Kovatchev, Harsimran Singh, Lars Mueller, Linda A. Gonder-Frederick; Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis. Diabetes Care 1 November 2022; 45 (11): 2636–2643. https://doi.org/10.2337/dc22-1217
CGM Insights: Unveiling Cutting-Edge Clinical Evidence for Type 2 Diabetes Management
Épisode 15
mardi 14 novembre 2023 • Durée 23:17
This is our third and final episode which was recorded at ADA – The American Diabetes Association conference held in San Diego earlier this year. In this episode, host Cher Pastore speaks to Dr Maggie Crawford, senior manager of translational and behavioral data science at Dexcom, to discuss findings from a few studies Dr Crawford was presenting at ADA. The first study, titled "Exploring the Impact of CGM on Perceived Control and Non-Intensive Insulin Treated Type Two Diabetes", explored how CGM use influenced individuals' perceptions of control over their diabetes. Participants monitored their glucose levels with Dexcom's CGM system over a three month period with no behavioural support. The second study investigated the impact of Dexcom's G6 real-time CGM on glucose metrics, self-reported body weight, and psychosocial health among customers living with type two diabetes and taking basal insulin. Maggie has a PhD public health, focusing on health behavior, and also earned a masters in public health in epidemiology. Maggie's personal and career goal is to help people understand their physiology and behaviors to help them feel in control of managing their health. She spends her free time surfing, backcountry skiing, climbing, running, and mountain biking-- and playing with her two vivacious babies. Her greatest accomplishment has been birthing two amazing humans 18 months apart while managing type 1 diabetes.Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. Dr Margaret Crawford is an employee of Dexcom. Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.Dexcom Provider website References:1. MARGARET A. CRAWFORD, CHRISTIAN HICKS, PAUL GENGE, KENNETH GREENAWALD, MICHELLE TRESSLER, DANIEL R. CHERÑAVVSKY, HARSIMRAN SINGH; 677-P: Exploring the Impact of CGM on Perceived Control of Non-Intensive Insulin Treated Type 2 Diabetes—“I liked keeping my line with as few spikes as possible”. Diabetes 20 June 2023; 72 (Supplement_1): 677–P. https://doi.org/10.2337/db23-677-P2. MARGARET A. CRAWFORD, CHRISTIAN HICKS, TERESA ZHOU, AFSHAN KLEINHANZL, HARSIMRAN SINGH; 63-LB: Real-Time Continuous Glucose Monitoring (rtCGM) Is Associated with Improved Clinical and Psychosocial Health in People with Type 2 Diabetes on Basal Insulin (T2D-BI). Diabetes 20 June 2023; 72 (Supplement_1): 63–LB. https://doi.org/10.2337/db23-63-LB
Mastering CGM: Real Stories and Expert Tips for Seamless Glucose Monitoring
Épisode 14
mardi 3 octobre 2023 • Durée 54:44
In the latest episode of Real Time Real Talk, we engage in an enlightening conversation on the progressive strides in diabetes management with our special guest, Dr. Nicholas Argento. With personal experience spanning over five decades of living with type one diabetes and leveraging his professional expertise in diabetes technology, Dr. Argento details the indispensable role that CGM plays in his life from diagnosis in 1968, the evolution of glucose monitoring, ie. From insulin to now integrating CGM with an automated insulin delivery devices and what the future could hold. In this insightful discussion, Dr. Argento also offers his first-hand experience with the Dexcom G6 device, drawing parallels between CGM and a personal GPS for glucose. He elaborates on the downside of the traditional finger sticks method of monitoring blood glucose levels and champions the CGM as a significant milestone in diabetes management. He also shares actionable strategies for dietary adjustments and lifestyle modification, emphasizing the link between diet, light exercises, and effective blood glucose level management. This is a fantastic episode with great takeaways, not just for those living with diabetes but also health care professionals. This episode was recoded at ADA - The American Diabetes Association in July 2023.Real-time real talk is intended for healthcare professionals in the US.Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Dr. Nicholas Argento MD, PhD is a paid spokesperson for Dexcom. About Hello Dexcom Dexcom Provider website Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References:1. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Sep;23(9):601-608. doi: 10.1089/dia.2021.0097. Epub 2021 Apr 21. PMID: 33784196; PMCID: PMC8501470.2. Tadej Battelino, et al; Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 1 August 2019; 42 (8): 1593–1603. https://doi.org/10.2337/dci19-0028
A Dynamic Duo: Dexcom & Omnipod
Épisode 13
mardi 12 septembre 2023 • Durée 39:29
Join us for an insightful journey into the world of diabetes management technology on this very special episode of Real-Time, Real Talk. Recorded live from the American Diabetes Association’s 83rd Scientific Sessions in San Diego, host Nancy Hanna is joined by Dexcom’s Cher Pastore in our very first simulcast. To explore how Dexcom and Omnipod are influencing the dynamics of diabetes technology and reshaping patient outcomes for the better, they’re joined by Dr. Viral Shah - an endocrinologist whose research into these innovative therapies has touched and improved countless lives. Across the episode, you'll discover how technological advancements are changing the game and reducing daily management burdens for people with diabetes. Hear invaluable insights from Dr. Shah on the importance of early adoption of tools and how they can prove pivotal in managing diabetes and improving glycemic control. Dr Shah examines the different barriers to technology adoption, and how fostering a pro-active conversation can help overcome them. All this, plus a sneak peek into the future of diabetes tech. Real-time real talk is intended for healthcare professionals in the US.Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G6-CGM-Users-Guide-new.pdf). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older.Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G6 app or receiver before making treatment decisions. Dr. Viral Shah MD, is a paid spokesperson for Dexcom. About Hello Dexcom (https://provider.dexcom.com/prescribe-sample#block-contactus) Dexcom Provider website (https://provider.dexcom.com/) Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References:1. Sue A. Brown, et al, Omnipod 5 Research Group; Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care 1 July 2021; 44 (7): 1630–1640. https://doi.org/10.2337/dc21-01722. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 Mar 1;45(3):750-753. doi: 10.2337/dc21-2004.3. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 Jan;21(1):6-10. doi: 10.1089/dia.2018.0257. 4. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52464&ver=49&contractorName=all&sortBy=updated&bc=135. Davis GM, Peters AL, Bode BW, Carlson AL, Dumais B, Vienneau TE, Huyett LM, Ly TT. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy. Diabetes Care. 2023 Apr 1;46(4):742-750. doi: 10.2337/dc22-1915. 6. Davis GM, et al. Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multi-Center, Single-arm, Feasibility Trial. Diabetes Technol Ther. 2023 Aug 14. doi: 10.1089/dia.2023.0304.
Beta Bionics iLet – The Ultimate Game Changer in Diabetes Care
Épisode 12
mercredi 23 août 2023 • Durée 56:41
In this month’s episode of Dexcom’s ‘Real Time Real Talk', host Cher Pastore talks to Beta Bionic’s Chief Medical Officer, Dr. Steven Russell about the iLet Bionic Pancreas - the revolutionary automated insulin delivery system from ADA - The American Diabetes Association held in San Diego. The iLet has been years in the making with Dr Ed Damiano, Beta Bionic’s founder starting this journey when his son was diagnosed with T1 diabetes aged just 11 months, to back in May when Beta Bionics have announced FDA Clearance and Commercialization of the iLet. Founded in 2015 explicitly to be a force for good for the diabetes community, the iLet ticks that box as it reduces the need to make decisions about your diabetes management – as it makes the decisions for you. No more carb counting, carb ratios, correction factors or pre-set Basal rates, How does it do that? By using a few algorithms: Basal, corrections and meal dose, and all you need to do to get started is to put your body weight in! Topics discussed in this episode include the journey of how the iLet came to be and how it differs from other automated insulin delivery systems in that it solves two notable challenges that have long burdened both type 1 diabetics and healthcare providers — carbohydrate counting and pre-bolusing. Dr Russell also discusses some of the findings from the extensive pivotal trials that took place, how the iLet is working with the Dexcom G6, some findings from the targeted initial launch and the roadmap Beta Bionics are planning for the future of the iLet. Whether you’re using the iLet, want to use it or are a Health Care Provider, this episode is not one to miss out.Real-time real talk is intended for healthcare professionals in the US.Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide (https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. In this month’s episode of Dexcom’s ‘Real Time Real Talk', host Cher Pastore talks to Beta Bionic’s Chief Medical Officer, Dr. Steven Russell about the iLet Bionic Pancreas - the revolutionary automated insulin delivery system from ADA - The American Diabetes Association held in San Diego. The iLet has been years in the making with Dr. Ed Damiano, Beta Bionic’s founder starting this journey when his son was diagnosed with T1 diabetes aged just 11 months, to back in May when Beta Bionics have announced FDA Clearance and Commercialization of the iLet. Founded in 2015 explicitly to be a force for good for the diabetes community, the iLet ticks that box as it reduces the need to make decisions about your diabetes management – as it makes the decisions for you. No more carb counting, carb ratios, correction factors or pre-set Basal rates, How does it do that? By using a few algorithms: Basal, corrections and meal dose, and all you need to do to get started is to put your body weight in! Topics discussed in this episode include the journey of how the iLet came to be and how it differs from other automated insulin delivery systems in that it solves two notable challenges that have long burdened both type 1 diabetics and healthcare providers — carbohydrate counting and pre-bolusing. Dr. Russell also discusses some of the findings from the extensive pivotal trials that took place, how the iLet is working with the Dexcom G6, some findings from the targeted initial launch and the roadmap Beta Bionics are planning for the future of the iLet. Whether you’re using the iLet, want to use it or are a Health Care Provider, this episode is not one to miss out.Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.Dr. Steven Russell MD, PhD is a Chief Medical Officer of Beta Bionics.About Hello Dexcom: https://provider.dexcom.com/prescribe-sample#block-contactusDexcom Provider website: https://provider.dexcom.com/About Beta Bionics: https://www.betabionics.com/Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate.BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.References:1. Lynch J, Kanapka LG, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Calhoun P, Beck RW. The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):726-736. doi: 10.1089/dia.2022.0341. PMID: 36173238; PMCID: PMC9529297.2. Beck RW, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Calhoun P. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):681-696. doi: 10.1089/dia.2022.0167. PMID: 36173235; PMCID: PMC9529301.3. Kruger D, Kass A, Lonier J, Pettus J, Raskin P, Salam M, Trikudanathan S, Zhou K, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Marak MC, Calhoun P, Beck RW. A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):697-711. doi: 10.1089/dia.2022.0200. PMID: 36173236; PMCID: PMC9634987.
Digital Health & Dexcom: The Role of CGM in Personalized Medicine
Épisode 10
mardi 4 juillet 2023 • Durée 27:32
In this podcast episode, host Cher Pastore speaks with Dr Reddy, a clinical endocrinologist at Carbon Health, a tech-enabled healthcare company on a mission to make great healthcare accessible by putting people first. Dr Reddy has used CGM for over 20 years and has developed innovative approaches to manage diabetes that incorporate CGM including a boot camp approach to uncontrolled type 2 diabetes, a CGM clinic and a therapeutic CGM training program.As an endocrinologist at Carbon Health, she sees patients completely virtually using a team based approach incorporating CGM. We discuss how the use of CGM and digital platforms can help improve outcomes for patients, she shares stories of patients using CGM and shares insights for other health care providers.Real-time real talk is intended for healthcare professionals in the US.DISCLAIMER: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the: Dexcom G7 User Guide: https://bit.ly/3MSkRUv For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. DEXCOM CLARITY SAFETY INFORMATION: The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. About Hello Dexcom: https://www.dexcom.com/en-us/get-started-cgm/11 Dexcom Provider website: https://provider.dexcom.com/
"Don’t let diabetes define your life": Dexcom Warrior Ariana Frayer on diagnosis, G7 and living with Type 1
Épisode 10
mardi 6 juin 2023 • Durée 40:23
In this podcast episode, host Cher Pastore speaks with Cup of OJ Founder, Ariana Frayer, who was diagnosed with type 1 diabetes aged 10.
Ariana shares her journey, what it was like growing up with diabetes, and how it impacted things like school and dating.
We also hear about her unique experience with CGM, what she likes about the G7, the differences from the G6 as well as her favourite features.
Lastly, we learn about a community she founded on Instagram and Cup of OJ to pursue her goal of sharing knowledge and inspiring growth, keeping herself accountable for her diabetes whilst uniting others who also share this experience.
Real-time real talk is intended for healthcare professionals in the US.
DISCLAIMER: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the:
Dexcom G7 User Guide: https://bit.ly/3MSkRUv
For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.
Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.
The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.
Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.
Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.
A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions.
Ariana Frayer is a paid spokesperson and a Dexcom Warrior.
BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
DEXCOM CLARITY SAFETY INFORMATION: The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.
About Hello Dexcom: https://www.dexcom.com/en-us/get-started-cgm/11
Dexcom Provider website: https://provider.dexcom.com/
What The Expanded CMS Guidelines Mean for your Medicare Patients
Épisode 9
lundi 15 mai 2023 • Durée 31:38
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. About New Expanded Medicare Guidelines About Hello Dexcom Dexcom Provider website About Medicaid coverage Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References 1. Dexcom G7 User Guide 2. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444 3. Aleppo G, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304. Epub 2021 Sep 29. PMID: 34588210; PMCID: PMC8669539. 4. Psavko S, Katz N, Mirchi T, Green CR. Usability and teachability of continuous glucose monitoring devices in older adults and diabetes educators: a task analysis and ease of use survey. JMIR Hum Factors. 2022 Nov 8. doi: 10.2196/42057 5. International Hypoglycemia Study Group. Diabetes Care. 2015;38:1583-1591. 6. Boureau AS, et al. Nocturnal hypoglycemia is underdiagnosed in older people with insulin-treated type 2 diabetes: The HYPOAGE observational study. J Am Geriatr Soc. 2023;1–13. DOI: 10.1111/jgs.18341. 7. Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 May;16(3):677-682. doi: 10.1177/1932296820982584. Epub 2021 Jan 5. PMID: 33401946; PMCID: PMC9294577. 8. Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. Diabetes Technol Ther. 2019 Apr;21(4):155-158. doi: 10.1089/dia.2018.0359. Epub 2019 Mar 22. PMID: 30896290; PMCID: PMC6477579. 9. Shichun Bao, Ryan Bailey, Peter Calhoun, and Roy W. Beck.Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin.Diabetes Technology & Therapeutics.May 2022.299-306.http://doi.org/10.1089/dia.2021.0494 10. By 2023, there had been 52 million ULS alerts from Dexcom CGM systems, and 11 million of those occurred during the night. Dexcom data on file, 2023.
Podcasts Similaires Basées sur le Contenu
Découvrez des podcasts liées à Real-Time Real Talk | Continuous Glucose Monitoring (CGM) Education for Healthcare Providers. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !
